Vibliome Therapeutics
Latest round
- Series A
Last raised
- Feb 2022
Total raised
- $38M
Investors
- 1
About Vibliome Therapeutics
Based in Massachusetts, US, and founded in 2017 by Gary Flynn, Vibliome Therapeutics, LLC, is a research-based organization involved in the study of small-molecule Type II Kinase inhibitors for the treatment of cancer and other diseases. Vibliome develops Type II inhibitors that bind to kinase targets and keep them in an inactive state. The firm enables early profiling of its Type II discovery library against a panel of more than 300 kinase targets, as opposed to target-driven high-throughput screening approaches. This method creates a SAR database that can be utilized to build new Type II kinase inhibitors to enhance precision medicine methods for cancer and other disorders that need selective kinase targeting.
Who invested in Vibliome Therapeutics
1 investor across 2 rounds
See all investors in Vibliome Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Vibliome Therapeutics
Who invested in Vibliome Therapeutics?
Vibliome Therapeutics has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Vibliome Therapeutics raised?
Vibliome Therapeutics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Vibliome Therapeutics last raise money?
Vibliome Therapeutics's most recent round on record is a Series A, in Feb 2022.
What does Vibliome Therapeutics do?
Based in Massachusetts, US, and founded in 2017 by Gary Flynn, Vibliome Therapeutics, LLC, is a research-based organization involved in the study of small-molecule Type II Kinase inhibitors for the treatment of cancer and other diseases.
Where is Vibliome Therapeutics headquartered?
Vibliome Therapeutics is headquartered in Bozeman, US.
Which VCs invest in companies like Vibliome Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Vibliome Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Vibliome Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.